HOOKIPA Pharma Inc. (HOOK), a clinical-stage biopharmaceutical company, announced on Thursday that enrollment has been completed in its Phase 1b clinical trial evaluating HB-500 for the treatment of HIV.
The trial, which enrolled 30 participants across five U.S. sites, is designed to assess the safety, tolerability, and immune responses to HB-500 in patients with HIV on suppressive antiretroviral treatment.
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences as part of a potential curative regimen for HIV.
The Phase 1b trial is evaluating two dose escalation cohorts, with participants receiving either HB-500 or a placebo.
The trial's primary completion is expected in the second half of 2025.
HOOKIPA is leading the HIV program through the completion of the Phase 1b trial, after which Gilead will have the exclusive right to continue the development.
HB-500 aims to induce durable immunity and could play a critical role in driving viral suppression and the eradication of the pro-viral reservoir, moving towards a functional cure for HIV.
The company continues to advance its strategic collaboration with Gilead in the development of HB-500 and other immunotherapies for serious infectious diseases.
Currently, HOOK is trading at $1.97 down by 1.00%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.